Stockscreener 앱 받기
0.7824
2.25%
0.0172
전일 마감가:
$0.7652
열려 있는:
$0.7666
하루 거래량:
303.03K
Relative Volume:
0.27
시가총액:
$87.93M
수익:
$3.17M
순이익/손실:
$-36.23M
주가수익비율:
-1.9139
EPS:
-0.4088
순현금흐름:
$-17.11M
1주 성능:
-2.44%
1개월 성능:
-19.53%
6개월 성능:
-48.53%
1년 성능:
+54.02%
1일 변동 폭
$0.7666
$0.7904
1주일 범위
$0.73
$0.81
52주 변동 폭
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
명칭
Rani Therapeutics Holdings Inc
전화
(408) 457-3700
주소
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7824 | 87.93M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-06-14 | 개시 | Maxim Group | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-07-27 | 개시 | H.C. Wainwright | Buy |
| 2022-06-13 | 개시 | Wedbush | Outperform |
모두보기
Rani Therapeutics Holdings Inc 주식(RANI)의 최신 뉴스
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rani Therapeutics Holdings Inc (RANI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rani Therapeutics Holdings Inc (RANI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rani Therapeutics Holdings Inc (RANI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RANI Stock Price, Quote & Chart - ChartMill
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Javadi Alireza - Moomoo
[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity - Stock Titan
Rani Therapeutics (RANI) grants CBO 805,500 stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options - Stock Titan
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A - Moomoo
Director Abraham Bassan receives 123,600 Rani (RANI) stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares - Stock Titan
Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options - Stock Titan
Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award - Stock Titan
Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price - Stock Titan
Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike - Stock Titan
Rani Therapeutics | 8-K: Current report - Moomoo
Rani Therapeutics (RANI) stockholders elect directors and ratify 2026 auditor - Stock Titan
Akkaraju funds lift Rani Therapeutics (RANI) beneficial stake to 9.99% - Stock Titan
Rani Therapeutics Announces $20 Million Equity Financing - The Globe and Mail
Rani Therapeutics to raise $20M in registered direct offering - MSN
Rani Therapeutics | 424B5: Prospectus - Moomoo
Rani Therapeutics Holdings, Inc. Announces Securities Purchase Agreement and Pre-Funded Warrant Offering – SEC 8-K Filing Details - Minichart
Rani Therapeutics (RANI) raises ~$19.99M via Class A shares and pre-funded warrants - Stock Titan
Rani Therapeutics to Raise ~$20M via $1.07 Share Offering and Pre-Funded Warrants - TradingView
Rani Therapeutics (RANI) prices $20M stock and pre-funded warrant sale - Stock Titan
Rani Therapeutics Prices Registered Direct Offering of 12.5 Million Shares - Moomoo
Rani Therapeutics prices $20M direct offering of Class A common stock at market price - Pluang
Rani Therapeutics raises $20 million in direct offering By Investing.com - Investing.com Nigeria
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 - GlobeNewswire
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com South Africa
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Holdings Inc (RANI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):